Group 1 - Emergent BioSolutions Inc. received an order worth up to $21.5 million from the US Department of War for the supply of BioThrax, the only FDA-approved anthrax vaccine [1][2] - Deliveries of BioThrax are expected to occur throughout 2026, with a one-year base period and optional extensions into 2027 and 2028, highlighting the company's ongoing role in US defense against biological threats [2] - The company announced a collaboration with PANTHER to fund the "MpOx Study in Africa," which is testing potential treatments for Mpox, positioning the company in a high-demand area amid ongoing outbreaks [3] Group 2 - Emergent BioSolutions is focused on providing solutions to public health threats, including opioid overdoses, infectious diseases, and biological threats [4]